Trial Profile
The Effect of Eplerenone on Ischemia Reperfusion Injury in Human Myocardium (EPLICARD Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary) ; Aldosterone
- Indications Reperfusion injury
- Focus Therapeutic Use
- Acronyms EPLICARD
- 11 Jan 2016 No of arms changed from 4 to 2 in which patients exposed to Caffeine and aldosterone are removed as per ClinicalTrials.gov record.
- 11 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 03 Jul 2015 New trial record